Home | Welcome to Contract Pharma   
Last Updated Saturday, May 30 2015


Financial Report: InterMune

Published May 2, 2014

1Q Revenues: $30.3 million (+188%)

1Q Loss: $53.6 million (loss of $49.9 million in 1Q13)

Comments: Esbriet revenue in the quarter was $30.3 million, up 188%. R&D expenses were $32.1 million, up 24%, attributed to activities to complete the ASCEND Phase III trial, a higher number of patients in the RECAP extension study of pirfenidone, and activities related to the pirfenidone NDA resubmission.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On